Agilent Technologies, Inc. $A Stock: Robeco Schweiz AG Cuts Stake

Robeco Schweiz AG lowered its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 931,998 shares of the medical research company’s stock after selling 75,587 shares during the quarter. Agilent Technologies makes up approximately 2.9% of Robeco Schweiz AG’s holdings, making the stock its 8th biggest position. Robeco Schweiz AG owned about 0.33% of Agilent Technologies worth $160,593,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. State Street Corp grew its position in Agilent Technologies by 0.7% during the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company’s stock valued at $1,710,658,000 after buying an additional 89,598 shares during the period. Wellington Management Group LLP raised its position in Agilent Technologies by 2.7% in the second quarter. Wellington Management Group LLP now owns 7,454,686 shares of the medical research company’s stock worth $990,206,000 after acquiring an additional 198,253 shares during the period. Deutsche Bank AG raised its position in Agilent Technologies by 17.1% in the second quarter. Deutsche Bank AG now owns 7,008,634 shares of the medical research company’s stock worth $930,957,000 after acquiring an additional 1,024,516 shares during the period. Bank of New York Mellon Corp raised its position in Agilent Technologies by 87.4% in the second quarter. Bank of New York Mellon Corp now owns 5,233,964 shares of the medical research company’s stock worth $695,227,000 after acquiring an additional 2,440,360 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Agilent Technologies by 9.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,108,764 shares of the medical research company’s stock worth $240,336,000 after acquiring an additional 185,223 shares during the last quarter.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $172.98 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.05 and a quick ratio of 1.56. Agilent Technologies, Inc. has a 1-year low of $108.35 and a 1-year high of $179.10. The company has a market capitalization of $48.77 billion, a P/E ratio of 34.05, a P/E/G ratio of 2.63 and a beta of 1.21. The firm’s 50 day simple moving average is $161.48 and its two-hundred day simple moving average is $139.62.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Research analysts expect that Agilent Technologies, Inc. will post 6.20 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 28th. Stockholders of record on Tuesday, October 6th will be paid a $0.2550 dividend. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.6%. Agilent Technologies’s dividend payout ratio is 20.08%.

Insider Activity

In related news, Director Mikael Dolsten sold 634 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the sale, the director owned 4,924 shares in the company, valued at approximately $745,395.12. This trade represents a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Rothschild & Co Redburn boosted their price objective on shares of Agilent Technologies from $160.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Sanford C. Bernstein raised their target price on Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. Wells Fargo & Company lifted their target price on Agilent Technologies from $160.00 to $180.00 and gave the company an “overweight” rating in a research report on Friday, August 28th. Finally, Royal Bank Of Canada boosted their price target on Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Seventeen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $181.00.

About Agilent Technologies

Agilent Technologies, Inc is a global provider of analytical laboratory instruments, software, services and consumables. The company serves customers in the pharmaceutical, biotechnology, chemical, food, environmental, energy and academic research sectors, as well as diagnostic and clinical laboratories.

Agilent’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic instruments, laboratory automation products, genomic and cell analysis solutions, and related software.